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Description
FIELD OF THE INVENTION
[0001] The present invention relates to new spirolactam compounds, to synthetic processes and intermediate com-
pounds for their preparation and to their use as UV absorbers.
BACKGROUND OF THE INVENTION
[0002] Lactams are compounds of high interest due to their biological activities, for example well known β-lactams
such as some penicillins, cephalosporins and carbapenems have antibacterial activity.
[0003] Spirolactams are one particular class of lactams that have shown interesting biological properties. Some
spiro-fused azetidinones have been described as having antibacterial activity, see US 4,680,388, or hypocholestero-
lemic properties, see for example WO 94 17038. Additionally, if these compounds have the adequate functionality they
are valuable intermediates towards different families of compounds. The spirolactam ring is the equivalent of an alpha
amino or hydroxy aminoacid and opens many possibilities in diastero and/or enantioselective synthesis.
[0004] There are few synthetic processes available for this class of compounds. WO 96 27587 describes the catalytic
enantioselective synthesis of certain spirolactams that involves a large number of steps. US 5,734,061 also describes
a process for the preparation of spirocyclic lactams N-substituted with a tertiary amine susbtituent. US 4,680,388 de-
scribes procedures to obtain N-sulphate substituted spirolactams. These processes and the intermediates used in
them are directed to very particular compounds and therefore lack a wider applicability due to the absence of reactive
functional groups.
[0005] Miyazawa, E. et al. in Heterocycles, vol 59, 1:149-160 "Synthesis of spiro-fused nitrogen heterocyclic com-
pounds via N-methoxy-N-acylnitrenium ions using phenyliodine (III) bis(trifluoroacetate) in trifluoroethanol" describe
another process to obtain functionalised spirolactams including some spirodienones.
[0006] Glover, S.A. et al. in Tetrahedron, 1987, 43:2577-2592 "N-alkoxy-N-acylnitrenium ions in intramolecular aro-
matic addition reactions" describe the synthesis in low yields of benzolactams via cyclization of N-alkoxy-N-acylni-
trenium ions.
[0007] Kawase, M. et al. in J. Org. Chem., 1989, 54:3394-3403 "Electrophilic aromatic substitution with N-methoxy-N-
acylnitrenium ions generated from N-chloro-N-methoxyamides: syntheses of Nitrogen heterocyclic compounds bearing
a N-methoxyamide group" describe among others the synthesis of spiro benzodienone lactams by ipso amidation with
a nitrenium ion.
[0008] These processes present serious inconvenients relating to their yields and to the limited stability of the spiro-
fused lactams obtained. Thus, any efficient process for producing functionalised spirolactam compounds in high yield,
with various functionalities such as a benzodienone group, and if necessary with stereospecificity, would be a wellcome
contribution to the art.
SUMMARY OF THE INVENTION
[0009] The invention provides very stable spiro-fused azatidinones which are useful as intermediate compounds in
the preparation of a variety of highly functionalised chemical structures, including, if necessary, diastero and/or enan-
tioselective processes.
[0010] In one aspect the invention provides a compound of formula I:
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wherein R1 and R2 are independently selected from H, halogen, protected or unprotected hydroxy, protected or un-
protected silyloxy, substituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkoxy or aryloxy, sub-
stituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, nitro, amino, mercapto or alkylthio;
R3 and R4 are independently selected from H, substituted alkyl, substituted or unsubstituted alkoxy or aryloxy, substi-
tuted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
Z is -(CRaRb)n- wherein n is a number selected from 1, 2, 3 and Ra and Rb are each independently selected from
hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alke-
nyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxy,
substituted or unsubstituted aryloxy, substituted or unsubstituted amino, or halogen;
Y is selected from -0-, -S-, -N(RaRb)- or -C(O)-, wherein Ra and Rb are as previously defined and do not form a cyclic
ring;
W is a group with sufficient electronic density to stabilize the compound throughπ (pi) interactions with the benzodienone
moiety; or a salt, complex or solvate thereof.
[0011] We have drastically increased the stability of these compounds through the selection of an adequate W group.
[0012] As a further advantage, the compound adopts a preferential conformation in which the W group blocks one
of the faces of the benzodienone, directing further reactions on the free face of the benzodienone moeity.
[0013] In addition, we have found that these compounds present interesting UV absorption properties which can be
modulated according to the substituents used.
[0014] Preferably W is a group having unsaturated bonds or aromatic groups, more preferably it is selected from
substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted alke-
nyl.
[0015] The invention also provides a process for producing a compound of formula I which comprises a step (a) of
reacting a compound of formula III:
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wherein R1, R2, R3, R4, Z, Y, W are as defined above,
R5 is hydrogen or substituted or unsubstituted alkyl;
Hal is F, Cl, Br, I or -SO2CF3;
with an N-acylnitrenium ion forming agent to produce a compound of formula I.
[0016] Preferably the process comprises the additional step (b) of preparing a compound of formula III by reacting
a compound of formula IV:
wherein wherein R1, R2, R3, R4, R5, Z, Y, W are as defined above,
with a Weinreb-type amide halogenating agent; preferably an agent selected from alkyl hypochlorite, alkyl hypobromite,
sodium bromite, sodium hypochlorite, benzyltrimethylammonium trihalide, N-halophthalimide , N-halosuccinimide or
phenyliodine (III) bis(trifluoroacetate) (PIFA). Most preferred is sodium hypochlorite.
[0017] Further, the invention provides intermediate compounds useful in the production of a compound of formula I
as defined above, such as compounds III and IV.
DETAILED DESCRIPTION OF THE INVENTION
[0018] Previously described compounds such as N-methoxy substituted spirobenzodienone are poorly stable and
tend to reverse to compounds structurally related to the starting products during their synthesis or purification because
of an easily triggered reduction process:
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[0019] Additionally, during their synthesis or during their purification, and depending on the substitution of the phenyl
acetamides starting materials, other aromatic heterocycles tend to be produced because of their higher stability (see
J. Org. Chem, 1989, 54: 2294-3403, scheme I):
[0020] We have now found a new class of compounds containing the spirolactam group and presenting a benzodi-
enone functionality that are remarkably stable and open to a large number of possibilities for further use. The stability
is present during synthesis and also in purification processes. In these compounds the above mentioned reactions are
avoided.
[0021] Without being bound by theory, we believe that the stability is provided by π interactions between the W group
attached to the hydroxilamino and the benzodienone functionality. This configuration has a further advantage in that
the W group covers one face of the benzodienone group, acting as a protecting group for one of the faces and directing
the attack of further reactives to the other face.
[0022] In the above definition of compounds of formula (I) and in the description the following terms have the meaning
indicated:
"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms, con-
taining no saturation, having one to eight carbon atoms, and which is attached to the rest of the molecule by a
single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, etc. Alkyl radicals may be optionally
substituted by one or more substituents independently selected from the group consisting of a halo, hydroxy, alkoxy,
carboxy, cyano, carbonyl, acyl, alkoxycarbonyl, amino, nitro, mercapto and alkylthio.
"Alkoxy" refers to a radical of the formula-ORa where Ra is an alkyl radical as defined above, e. g., methoxy,
ethoxy, propoxy, etc. "Aryloxy" refers to a radical of formula -ORb wherein Rb is an aryl radical as defmed below.
"Amino" refers to a radical of the formula-NH2-, -NHRa, -NRaRb.
"Aryl" refers to a phenyl, naphthyl or anthracyl radical. The aryl radical may be optionally substituted by one or
more substituents selected from the group consisting of hydroxy, mercapto, halo, alkyl, phenyl, alkoxy, haloalkyl,
nitro, cyano, dialkylamino, aminoalkyl, acyl and alkoxycarbonyl, as defined herein.
"Aralkyl" refers to an aryl group linked to an alkyl group such as benzyl and phenethyl.
"Cycloalkyl" refers to a saturated carbocyclic ring having from 3 to 8 carbon atoms.
"Heterocycle" refers to a heterocyclyl radical. The heterocycle refers to a stable 3-to 15- membered ring which
consists of carbon atoms and from one to five heteroatoms selected from the group consisting of nitrogen, oxygen,
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and sulfur, preferably a 4-to 8-membered ring with one or more heteroatoms, more preferably a 5-or 6-membered
ring with one or more heteroatoms. For the purposes of this invention, the heterocycle may be a monocyclic,
bicyclic or tricyclic ring system, which may include fused ring systems; and the nitrogen, carbon or sulfur atoms in
the heterocyclyl radical may be optionally oxidised; the nitrogen atom may be optionally quatemized; and the
heterocyclyl radical may be partially or fully saturated or aromatic. Examples of such heterocycles include, but are
not limited to, azepines, benzimidazole, benzothiazole, furan, isothiazole, imidazole, indole, piperidine, piperazine,
purine, quinoline, thiadiazole, tetrahydrofuran.
[0023] References herein to substituted groups in the compounds of the present invention refer to the specified
moiety that may be substituted at one or more available positions by one or more suitable groups, e. g., halogen such
as fluoro, chloro, bromo and iodo ; cyano ; hydroxyl ; nitro ; azido ; alkanoyl such as a C1-6 alkanoyl group such as
acyl and the like ; carboxamido ; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to
about 6 carbon atoms and more preferably 1-3 carbon atoms ; alkenyl and alkynyl groups including groups having one
or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms ; alkoxy groups having
one or more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms ; aryloxy such as
phenoxy ; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12
carbon atoms or from 1 to about 6 carbon atoms ; alkylsulfinyl groups including those moieties having one or more
sulfinyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ; alkylsulfonyl groups including
those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon
atoms ; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from
1 to about 6 carbon atoms ; carbocylic aryl having 6 or more carbons, particularly phenyl or naphthyl and aralkyl such
as benzyl. Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable
position of the group, and each substitution is independent of the other.
[0024] Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ
only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures
except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-
enriched carbon or 15N-enriched nitrogen are within the scope of this invention.
[0025] Salts of compounds of the invention are synthesized from the parent compound which contains a basic or
acidic moiety by conventional chemical methods. Generally, such salts are, for example, prepared by reacting the free
acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an
organic solvent or in a mixture of the two. Generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol
or acetonitrile are preferred. Examples of the acid addition salts include mineral acid addition salts such as, for example,
hydrochloride, hydrobromide, hydroiodide, sulphate, nitrate, phosphate, and organic acid addition salts such as, for
example, acetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulphonate and
p-toluenesulphonate.
[0026] The compounds of the invention may be in crystalline form either as free compounds or as solvates (e.g.
hydrates) and it is intended that both forms are within the scope of the present invention. Methods of solvation are
generally known within the art.
[0027] The compounds of the present invention represented by the above described formula (I) may include enan-
tiomers depending on the presence of chiral centres or isomers depending on the presence of multiple bonds (e.g. Z,
E). The single isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present
invention.
[0028] In the compound of formula I R3 and R4 are preferably H. Other substituents such as halogen or unsubstituted
alkyl are more difficult to produce because of the formation of indol type of compounds instead of the lactam.
[0029] In the compound of formula I substituents R1 and R2 should not be strongly electrophilic because during the
synthesis and depending on the method used they could difficult the attack of the nitrenium ion. Preferably they are
each independently selected from hydrogen, halogen, susbtituted aryl, more preferably they are both hydrogen.
[0030] In the compounds of formula I, the group Z gives rise to a ring of 4, 5 or 6 members. Substitution on position
Z creates a stereogenic center that could induce selective functionalisation on the benzodienone moiety. In a preferred
embodiment Z is - (CH2)n-. Although rings of 5 or 6 are also comprised within the scope of the invention, in one em-
bodiment the β-lactam ring (n= 1) is preferred because of the further uses that can be given to such compounds.
[0031] The group Y in the compounds of formula I, plays a role in the stability and conformation and also during its
synthesis. In an embodiment Y is preferably -0-, although other atoms are not excluded as long as the final product is
stable.
[0032] As we already mentioned the W group is important for the stabilization of the compound of formula I. Preferably
it comprises unsaturated bonds or aromatic groups to increase the pi interaction. Aralkyl groups and alkenyl groups
are preferred since they give the best stability. In a particular embodiment, W is -CRaRb-Q or -SiRaRb-Q since the
stability of the conformation is further improved by the presence of a -CRaRb- or a - SiRaRb- linker between Y and
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the substituent Q which has π (pi) interactions with the benzodienone moiety. The linker is preferably -CHRa-. In this
case a stereogenic center is introduced which allows for the selectivity or specificity of any further reaction, distinguish-
ing the two double bonds of the benzodienone. This will advantageously open the way to diastero- and/or enantiose-
lective synthesis in addition to the selection for one face which is mentioned above. Depending on the size of Ra it can
also modulate the π (pi) interactions and thus modulate properties such as UV absorption.
[0033] In one embodiment the W is an aralkyl group. Among the aryl groups susbtituted or unsubstituted phenyl and
naphthyl are preferred. Heterocyclylalkyl groups are also envisaged.
[0034] In one embodiment the compounds of formula II are preferred:
[0035] Wherein W is as above defined. A particularly stable compound according to formula II has W = benzyl.
[0036] The compounds of formula (I) defined above can be obtained by available synthetic procedures. Some ex-
amples of these procedures are described in the documents mentioned above. Particularly good results are obtained
forming the spiro lactam ring through reduction of an aromatic compound via a N-acylnitrenium ion.
[0037] Therefore in one aspect the invention is directed to a process of preparing a compound of formula I as defined
above which comprises the step (a) of reacting a compound of formula III:
wherein R1, R2, R3, R4, Z, Y, W are as defined above; R5 is hydrogen or susbtituted or unsubstituted alkyl; Hal is F,
Cl, Br, I or eventually -SO2CF3; with an N-acylnitrenium ion forming agent to produce a compound of formula I.
[0038] If Hal is an halogen, an adequate precipitating agent will be able to form the nitrenium ion. In general silver
salts give good results, other salts can be used.
[0039] R5 is preferably an electron-donating group, to promote the ipso addition of the nitrenium ion. Preferably R5
is alkyl such as methyl, ethyl, propyl, etc. Most preferably it is methyl.
[0040] An adequately susbtituted amino group can be used as an alternative to the -OR5 group, in this case the
addition of the nitrenium ion will generate the iminium salt of the benzodienone which by hydrolysis generates the
benzodienone. In this alternative, it is preferred that the substituents on the N atom be electro donating groups, such
as dialkylamine. Another possibility is to use an halogen group instead of -OR5 as described in J. Org. Chem., 2003,
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68: 6739-6744.
[0041] The reaction is preferably carried out in absence of light to avoid undesired radical reactions such the formation
of the alkoxyamide starting material rather than ipso amidation (addition), or decomposition of compounds of formula III.
[0042] Preferably the solvent should be polar, such as for example trifluoroacetic acid or acetic acid. A temperature
of about -10°C to about 10°C is preferred, more preferably of about O°C. The reaction can be carried out under inert
atmosphere if necessary. The obtained product of formula I can be purified following standard procedures such as
evaporation, chromatography, phase separation (extraction). As previously mentioned the product is stable and can
be stored for a prolongued period of time.
[0043] The compound of formula III is preferably prepared from a Weinreb-type amide compound of formula IV:
wherein R1, R2, R3, R4, R5, Z, Y, W are as defined above, by reaction with an halogenating agent. The halogenating
agent is preferably an agent selected from alkyl hypochlorite, alkyl hypobromite, sodium bromite, sodium hypochlorite,
benzyltrimethylammonium trihalide, N-halosuccinimide, N-halophthalimide or phenyliodine (III) bis(trifluoroacetate)
(PIFA). Sodium hypochlorite is preferred because of its low cost and availability.
[0044] The halogenation is preferably carried out in an apolar sovent, such as acetone, and at a temperature of about
-10°C to about 10°C, more preferably of about O°C. The reaction is preferably carried out in absence of light to avoid
undesired radical reactions.
[0045] The compounds of formula IV are either commercially available or easily prepared following known procedures
as described for example in the above mentioned references.
[0046] The processes above described provide a quick and easy way (3 steps) to obtain the stable compounds of
formula I.
[0047] The possibility of the preparation of new lactams, which are stable, densely functionalised and well suited to
control further reactions opens a large number of possibilities for further use. The compounds of formula I are useful
starting materials to produce a variety of chemical structures of interest. The double bond can be subjected to elec-
trophilic attacks with for example hydroxylating agents, epoxydation agents, reduction agents, as well as cycloadditions
and Michael reactions.
[0048] RMN and UV spectroscopic data (see examples section) for compounds described by formula I, are in com-
plete agreement with the presence of π interactions between their benzodienone portion and the Y-X substitution for
the cases in which the π-electrons are adequately orientated.
[0049] Thus, from the comparison between the 1H RMN data (chemical shifts and coupling constants) for compounds
3a, 3b, 3c y 3d (examples of formula IV) and compounds 5a, 5b, 5c y 5d (examples of formula I) it became evident
that compounds 5c and 5d have to present the above indicated π interactions. For compound 5d, the huge difference
between the four signals assigned to the four protons of its benzodienone portion has to be correlated to the interaction
between this moiety and its Y-X portion. In addition, we propose that this interaction is enhanced by a Thorpe-Ingold
effect.
[0050] Furthermore, the UV date for compounds 3a, 3b, 3c y 3d (examples of formula IV) and compounds 5a, 5b,
5c y 5d (examples of formula I) (see examples section) support our conclusions from their 1H RMN data. While the
spectra for 3a, 3b, 3c y 3d (examples of formula IV) present at 276 nm theirs maximum absorption (λmax) and this is
with independence of theirs Y-W substitution or Y-X, respectively, the situation for examples of formula I is completely
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different. Compounds 5a and 5b present at 243 nm theirs maximum absorptions (λmax), and compounds 5c and 5b at
242 y 232 nm, respectively. The variation of 11 nm into the maximum absorption (λmax) between compound 5d and
compound 5a is assigned to the interaction between its benzodienone portion moiety and its Y-X portion.
[0051] The knowledge of the structural basis (the establishment of π interactions between their benzodienone portion
and the Y-X substitution) for the above features spans the scope of their accessibility and applicability. From their
absorption data it is clear that both the range of absorption and the possibility to modulate this range by selection the
appropriate substituents makes these compounds useful materials as UV absorbers.
[0052] The following examples are intended to exemplify the invention, and should not be construed as limiting the
disclosure of the claimed invention.
EXAMPLES
General Methods and Materials.
[0053] All reactions described below were carried out under argon atmosphere unless otherwise noted. The solvents
used were distilled and dried under argon atmosphere before use (CH2Cl2 and benzene were distilled over CaH2).
Flash Chromatography was executed on columns loaded with 230-400 mesh silica gel Merck. TLC was carried out on
silica gel Merck (Kieselgel 60F-254).
[0054] All starting materials were purchased commercially (Aldrich, Fluka and Merck) and used without further pu-
rification, except the N-alcoxyamine 2d, which was prepared according to a literature procedure (see below). A com-
mercial household bleach solution Mavy® which is stated to be <5% NaOCl was used for the preparation of t-butyl
hypochlorite following the procedure described below.
[0055] Melting points (mp) were determined on a Reichert Microscopic Hot-Stage and are uncorrected. 1H and 13C
NMR spectra were measured on a Varian Gemini-200 and a Varian Inova-300 spectrometer with (CH3)4Si as an internal
reference and CDCl3 as solvent unless otherwise noted. Both 1H and 13C NMR spectral data are reported in parts per
million (δ) relative to residual sign of the solvent (CDCl3, 7.26 ppm and 77.0 ppm for 1H and 13C NMR, respectively). 1H
and 13C NMR designations are: s (singlete); s br. (broad singlete); d (doublete); t (triplete); q (quartete); m (multiplete).
Infrared (IR) spectra were record on a Perkin-Elmer FT-IR spectrometer. UV spectra were record on a Perkin-Elmer
402 spectrometer. Low-resolution mass (LRMS) spectra were obtained on a Hewlett Packard 5973 MSD spectrometer
with a direct inlet system (EI) at 70 eV. Microanalytical data (E.A.) were obtained on a Perkin-Elmer 240C and Heraus
CHN-O instruments at the Instrumental Analysis Department of Instituto de Química Orgánica General (C.S.I.C.).
Example 1:
General Procedure for the Preparation of the N-Alcoxyamides 3a-d from the 4-Methoxyphenylacetyl Chloride
(1).
[0056]
[0057] The N-alcoxyamines 2a-c were purchased from Aldrich and Fluka Companies, and used without further pu-
rification. The N-alcoxyamine 2d was prepared following the procedure described in Brown, D. S.; Gallagher, P. T.;
Lightfoot, A. P.; Moody, C. J.; Slawin, A. M. Z.; Swann, E. Tetrahedron 1995, 51, 11473-11488.
[0058] To a vigorously stirred solution of N-alcoxyamine hydrochloride 2a-d (17.87 mmol) and sodium carbonate
(32.50 mmol) in a mixture of benzene (23 ml) and H2O (23 ml) with ice-water bath cooling, was added 4-methoxyphe-
nylacetyl chloride (1). The mixture was stirred at room temperature for 12 h under an argon atmosphere and the progress
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of the reaction was monitored by TLC (hexane-AcOEt, 1:2). Then, AcOEt (50 ml) was added and the organic layer
separated. This process was repeated three times. The combined extracts were washed with brine (2 x 50 ml), dried
over Na2SO4, filtered and concentrated under reduced pressure to give the corresponding N-alcoxyamide 3a-d, which
was used in the next reaction without further purification.
Example 2:
N-Methoxy-4-methoxyphenylacetamide (3a)
[0059] The compound was obtained from 1 and 2a as described in Kawase, M. et al J. Org. Chem., 1989, 54:
3394-3403 "Electrophilic aromatic substitution with N-methoxy-N-acylnitrenium ions generated from N-chloro-N-meth-
oxyamides: syntheses of Nitrogen heterocyclic compounds bearing a N-methoxyamide group".
[0060] Rf = 0.14 (TLC, hexane-AcOEt, 1:2); yield, 99%; white solid, mp 86-87 °C (lit. mp 83-85 °C); 1H-NMR (200MHz,
CDCl3): δ 7.88 (1H, s br., NH), 7.19 (2H, d, J = 8.7 Hz, H-2), 6.88 (2H, d, J = 8.7 Hz, H-3), 3.81 (3H, s, OCH3), 3.71
(3H, s, NOCH3), 3.50 (2H, s, CH2); 13C-NMR (75MHz, CDCl3): δ 169.1, 158.5, 130.1, 126.1, 113.9, 63.8, 55.1, 39.1;
IR (KBr): ν 3467, 3159, 2967, 1644, 1612, 1513, 1252, 1063, 1033 cm-1; UV (MeOH): λmax (ε) = 276 nm (1619
l·mol-1·cm-1); LRMS(EI): m/z 195(M+, 3), 165(1), 160(1), 148(6), 135(4), 121(100), 91(23), 78(66); E.A. (C10H13NO3):
calculated C, 61.53; H, 6.71; found C, 61.61; H, 6.76.
Example 3:
N-(O-Allylhydroxyl)-4-methoxyphenylacetamide (3b)
[0061] Following the same procedure as in example 1 but starting from 2b we obtained compound 3b.
[0062] Rf = 0.30 (TLC, hexane-AcOEt, 1:2); yield, 99%; white solid, mp 100-101 °C; 1H-NMR (200MHz, CDCl3): δ
7.85 (1H, s br., NH), 7.18 (2H, d, J = 8.5 Hz, H-2), 6.87 (2H, d, J = 8.5 Hz, H-3), 5.89 (1H, m, CH=CH2), 5.31 (1H, s
br., CH=CH2), 5.25 (1H, s br., CH=CH2), 4.32 (2H, d, OCH2), 3.80 (3H, s, OCH3), 3.49 (2H, s, CH2); 13C-NMR (75MHz,
CDCl3): δ 169.1, 158.5, 131.9, 130.0, 126.2, 120.2, 113.8, 76.9, 55.0, 39.2; IR (KBr): ν 3467, 2967, 1641, 1609, 1514,
1253, 1057 cm-1; UV (MeOH): λmax (ε) = 276 nm (2070 l·mol-1·cm-1); LRMS(EI): m/z 221(M+, 37), 180(3), 161(16),
148(33), 135(9), 121(100), 91(17), 78(31); E.A. (C12H15NO3): calculated C, 65.14; H, 6.83; found C, 65.21; H, 6.89.
Example 4:
N-Benzyloxy-4-methoxyphenylacetamide (3c)
[0063] Following the same procedure as in example 1 but starting from 2c we obtained compound 3c.
[0064] Rf = 0.40 (TLC, hexane-AcOEt, 1:2); yield, 99%; white solid, mp 98-99 °C; 1H-NMR (200MHz, CDCl3): δ 7.71
(1H, s br., NH), 7.34 (5H, s br., Ph), 7.11 (2H, d, J = 8.5 Hz, H-2), 6.83 (2H, d, J = 8.5 Hz, H-3), 4.86 (2H, s, OCH2Ph),
3.79 (3H, s, OCH3), 3.45 (2H, s, CH2); 13C-NMR (75MHz, CDCl3): δ 168.9, 158.5, 135.0, 130.0, 129.01, 128.4, 128.3,
126.0, 113.9, 77.8, 55.0, 39.3; IR (KBr): ν 3436, 3159, 2965, 1644, 1611, 1512, 1252, 1059, 1032, 726, 696 cm-1; UV
(MeOH): λmax (ε) = 276 nm (1558 l·mol-1·cm-1); LRMS(EI): m/z 271(M+, 14), 239(2), 211(6), 193(1), 180(2), 165(3),
148(5), 121(71), 91(100), 77(29); E.A. (C16H17NO3): calculated C, 70.83; H, 6.32; found C, 70.87; H, 6.35.
Example 5:
(-)-(S)-N-(1-Phenylethoxy)-4-methoxyphenylacetamide (3d)
[0065] Following the same procedure as in example 1 but starting from 2d we obtained compound 3d.
[0066] Rf = 0.32 (TLC, hexane-AcOEt, 1:1); yield, 99%; white solid, mp 60-61 °C; [α]D20 = - 168.2° (c 1.1,
CHCl3); 1H-NMR (200MHz, CDCl3): δ 7.56 (1H, s br., NH), 7.32 (5H, m, Ph), 6.98 (2H, d, J = 7.1 Hz, H-2), 6.77 (2H,
d, J = 7.1 Hz, H-3), 4.98 (1H, m, OCH(CH3)Ph), 3.78 (3H, s, OCH3), 3.35 (2H, s, CH2), 1.53 (3H, d, J = 6.6 Hz,
CH3); 13C-NMR (75MHz, CDCl3): δ 168.5, 158.1, 140.6, 129.7, 128.0, 127.8, 126.6, 126.3, 113.5, 82.5, 54.7, 38.8,
20.4; IR (KBr): ν 3202, 3057, 2956, 2927, 2847, 1652, 1609, 1512, 1455, 1301, 1247, 1178, 1035, 700 cm-1; UV
(MeOH): λmax (ε) = 276 nm (1841 l·mol-1·cm-1); LRMS(EI): m/z 285(M+, 3), 268(2), 181(6), 165(2), 148(6), 121(40),
105(100), 91(5), 77(17); E.A. (C17H19NO3): calculated C, 71.56; H, 6.71; found C, 71.62; H, 6.75.
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Example 6:
General Procedure for the Preparation of the Spiro-Lactams 5a-d.
[0067] First, the compound t-Butyl Hypochlorite was prepared following the procedure described in Mintz, M. J.;
Walling, C. Org. Syntheses 1969, 49, 9-12:
[0068] To a vigorously stirred commercial household bleach solution (500 ml) was added, at 10 °C in the dark and
in a single portion, a solution of tert-butyl alcohol (37 ml, 0.39 mol) and glacial acetic acid (24.5 ml, 0.43 mol). The
reaction mixture was stirred for about 3 min, and then was poured into separatory funnel. The lower aqueous layer
was discarded, and the oily yellow organic layer was washed first with 10% aqueous Na2CO3 solution (50 ml) and then
H2O (50 ml). The product was dried over CaCl2 (1 g) and filtered. The product can be stored in refrigerator over CaCl2
in amber glass bottles. The t-butyl hypochlorite isolated by this procedure could be used in the next reaction without
further purification.
[0069] To a stirred solution of a N-alcoxyamide 3a-d (7.37 mmol) in CH2Cl2 (30 ml) was added slowly, at 0 °C in the
dark, freshly prepared tert-butyl hypochlorite (9.21 mmol). Alternatively, sodium hypochlorite such as commercial
household bleach solution Mavy® is used, at room temperature in the dark. The resulting mixture was stirred at 0 °C
(or in the case of bleach added, at room temperature) in the dark under an argon atmosphere until the disappearance
of starting material by TLC (hexane-AcOEt, 1:2) was observed (the time required was generally less than 30 min). The
solvent was evaporated in the dark under reduced pressure and the residue, the N-chloro-N-alcoxyamide 4a-d as a
yellow solid (Rf ≈ 0.83, hexane-AcOEt, 1:2), was used in the next reaction without further purification.
[0070] To solid N-chloro-N-alcoxyamide 4a-d cooled at 0 °C and under an argon atmosphere, was added a solution
of silver carbonate (14.74 mmol) in TFA (30 ml) in the dark with stirring. The mixture was stirred until the reaction was
complete, generally 30 min (TLC monitoring, hexane-AcOEt, 1:2), and then the solvent was removed under pressure
below 35 °C. The residue was basified with 5% aqueous Na2CO3 solution (75 ml) with cooling. The precipitated silver
salts were filtered through Celite in vacuum, and the pad was washed with CH2Cl2. The aqueous solution was extracted
with CH2Cl2 (3 x 150 ml). The combined extracts was washed with brine (2 x 150 ml), dried over Na2SO4 and concen-
trated under reduced pressure. The residue was purified by silica gel column chromatography (hexane-AcOEt) to give
the spiro β-lactam 5a-d.
1-Methoxy-1-azaspiro[3.5]nona-5,8-diene-2,7-dione (5a)
[0071] Flash chromatography (hexane-AcOEt, 1:1). Rf = 0.33 (TLC, hexane-AcOEt, 1:2); yield, 43%; pale brown
solid, mp 107-109 °C; 1H-NMR (200MHz, CDCl3): δ 6.91 (2H, d, J = 10.2 Hz, CH=CHCO), 6.46 (2H, d, J = 10.2 Hz,
CH=CHCO), 3.77 (3H, s, OCH3), 2.97 (2H, s, CH2); 13C-NMR (75MHz, CDCl3): δ 184.2, 162.2, 145.5, 132.5, 65.5,
60.4, 43.6; IR (KBr): ν 3436, 3014, 2934, 1772, 1667, 1630, 1404, 1060, 880 cm-1; UV (MeOH): λmax (ε) = 243 nm
(11959 l·mol-1·cm-1); LRMS(EI): m/z 179(M+, 1), 164(1), 151(2), 137(100), 106(3), 78(6); E.A. (C9H9NO3): calculated
C, 60.33; H, 5.06; found C, 60.39; H, 5.10.
1-(O-Allylhydroxyl)-1-azaspiro[3.5]nona-5,8-diene-2,7-dione (5b)
[0072] Flash chromatography (hexane-AcOEt, 3:2). Rf = 0.40 (TLC, hexane-AcOEt, 1:2); yield, 68%; yellow
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oil; 1H-NMR (200MHz, CDCl3): δ 6.89 (2H, d, J = 10.1 Hz, CH=CHCO), 6.44 (2H, d, J = 10.1 Hz, CH=CHCO), 5.97-5.83
(1H, m, CH2-CH=CH2), 5.37 (1H, m, CH2-CH=CH2), 5.32 (1H, m, CH2-CH=CH2), 4.35 (2H, d, J = 6.3 Hz, CH2-CH=CH2),
2.96 (2H, s, CH2); 13C-NMR (75MHz, CDCl3): δ 183.9, 162.6, 145.7, 131.6, 131.4, 128.7, 77.8, 60.1, 42.9, 12.8; IR
(NaCl, CCl4): ν 3536, 3050, 2927, 1783, 1669, 1631, 1401, 1251, 1052, 940, 880, 839 cm-1; UV (MeOH): λmax (ε) =
243 nm (12549 l·mol-1·cm-1); LRMS(EI): m/z 205(M+, 1), 177(3), 163(79), 147(34), 133(36), 120(8), 106(89), 78(100);
E.A. (C11H11NO3): calculated C, 64.38; H, 5.40; found C, 64.44; H, 5.44.
1-Benzyloxy-1-azaspiro[3.5]nona-5,8-diene-2,7-dione (5c)
[0073] The purity of spiro-lactam 5c is related to the concentration of the household bleach solution used. 1H NMR
spectra have to be used by the determination of spiro-lactam / N-alcoxyamide (5c : 3c) ratio. By TLC both compounds
have the same Rf (0.40, hexane-AcOEt, 1:2).
Flash chromatography (hexane-AcOEt, 2:1). Rf = 0.40 (TLC, hexane-AcOEt, 1:2); yield, 68%; pale brown-reddish solid,
mp 77-79 °C; 1H-NMR (200MHz, CDCl3): δ 7.32 (5H, m, Ph), 6.55 (2H, d, J = 10.2 Hz, CH=CHCO), 6.17 (2H, d, J =
10.2 Hz, CH=CHCO), 4.88 (2H, s, OCH2Ph), 2.89 (2H, s, CH2); 13C-NMR (75MHz, CDCl3): δ 183.8, 162.9, 145.0,
134.2, 130.9, 128.7, 128.6, 128.1, 78.7, 60.0, 42.9; IR (KBr): ν 3459, 3043, 2963, 1764, 1672, 1630, 1375, 1056, 886,
841, 768, 737, 696 cm-1; UV (MeOH): λmax (ε) = 242 nm (9511 l·mol-1·cm-1); LRMS(EI): m/z 255(M+, 1), 197(41), 121
(6), 106(16), 91(100), 78(25); E.A. (C15H13NO3): calculated C, 70.58; H, 5.13; found C, 70.63; H, 5.18.
(-)-(S)-1-(1-Phenylethoxy)-1-azaspiro[3.5]nona-5,8-diene-2,7-dione (5d)
[0074] Flash chromatography (hexane-AcOEt, 3:2). Rf = 0.47 (TLC, hexane-AcOEt, 1:2); yield, 55%; brown oil; [α]D20
= -63.6° (c 1.0, CHCl3); 1H-NMR (200MHz, CDCl3): δ 7.30-7.17 (5H, m, Ph), 6.67 (1H, dd, J = 10.0, 2.9 Hz, CH=CHCO),
6.23 (1H, dd, J = 10.0, 2.0 Hz, CH=CHCO), 6.11 (1H, dd, J = 10.0, 2,9 Hz, CH=CHCO), 5.81 (1H, dd, J = 10.0, 2.0
Hz, CH=CHCO), 4.88 (1H, q, J = 6.6 Hz, OCH(CH3)Ph), 2.75 (2H, s, CH2), 1.44 (3H, d, J = 6.6 Hz, CH3); 13C-NMR
(75MHz, CDCl3): δ 184.2, 163.8, 145.4, 144.9, 140.1, 131.9, 130.5, 128.9, 128.6, 127.1, 85.0, 60.5, 43.4, 20.7; IR
(NaCl, CCl4): ν 3289, 2978, 2927, 1784, 1668, 1630, 1512, 1454, 1249, 1050, 700 cm-1; UV (MeOH): λmax (e) = 232
nm (3083 l·mol-1·cm-1); LRMS(EI): m/z 269(M+, 1), 181(1), 165(1), 155(1), 148(1), 121(26), 105(100), 77(19) ; E.A.
(C16H15NO3): calculated C, 71.36; H, 5.61; found C, 71.40; H, 5.67.
Claims
1. A compound of formula I:
wherein R1 and R2 are independently selected from H, halogen, protected or unprotected hydroxy, silyloxy, sub-
stituted or unsubstituted alkyl or cycloalkyl, substituted or unsubstituted alkoxy or aryloxy, substituted or unsubsti-
tuted aryl, substituted or unsubstituted heterocyclyl, nitro, amino, mercapto or alkylthio;
R3 and R4 are independently selected from H, substituted alkyl, substituted or unsubstituted alkoxy or aryloxy,
substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl;
Z is -(CRaRb)n- wherein n is a number selected from 1, 2, 3 and Ra and Rb are each independently selected from
hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted
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alkoxy, substituted or unsubstituted aryloxy, substituted or unsubstituted amino or halogen;
Y is selected from -O-, -S-, -N(RaRb)- or -C(O)-, wherein Ra and Rb are as previously defined and do not form a
cyclic ring;
W is a group with sufficient electronic density to stabilize the compound through π interactions with the benzodi-
enone moiety; preferably a group selected from substituted or unsubstituted arylalkyl, substituted or unsubstituted
heterocyclylalkyl, substituted or unsubstituted alkenyl;
or a salt, complex or solvate thereof.
2. A compound as defined in claim 1 wherein R3 and R4 are H.
3. A compound as defined in claims 1 or 2 wherein R1 and R2 are each independently selected from hydrogen,
halogen and susbtituted aryl.
4. A compound as defined in claim 3 wherein R1 and R2 are H.
5. A compound as defined in anyone of claims 1-4 wherein Z is -(CHRa)n- , Ra and n being as defined in claim 1.
6. A compound as defined in claim 5, wherein n is 1.
7. A compound as defined in claim 5 or 6 wherein Ra is H.
8. A compound as defined in anyone of claims 1-7 wherein Y is -O- .
9. A compound as defined in anyone of claims 1-8 wherein W is -CRaRb-Q, wherein Ra and Rb are as previously
defined and Q is substituted or unsubstituted aryl, substituted or usubstituted heterocyclyl, substituted or unsub-
stituted alkenyl.
10. A compound as defined in claim 9 wherein Ra and Rb are H.
11. A compound as defined in claim 10 wherein Q is aryl, preferably phenyl.
12. A compound of formula II:
wherein W is as defined in claim 1 or 9.
13. A compound as defined in claim 12, wherein W is -CH2-Q, and Q is substituted or unsubstituted aryl, substituted
or unsubstituted alkenyl; preferably substituted or unsubstituted phenyl or vinyl.
14. A compound as defined in claim 13, wherein Q is phenyl.
15. A process for producing a spirolactam compound as defined in anyone of claims 1-14 which comprises the step
(a) of reacting a compound of formula III:
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wherein R1, R2, R3, R4, Z, Y, W are as defined in claim 1
R5 is hydrogen or susbtituted or unsubstituted alkyl;
Hal is F, Cl, Br, I or -SO2CF3;
with an N-acylnitrenium ion forming agent to produce a compound of formula I.
16. A process as defined in claim 15 wherein the N-acylnitrenium ion forming agent is an halogen precipitating agent,
preferably a silver salt.
17. A process as defined in claim 15 or 16 wherein the step (a) is carried out in the absence of light.
18. A process according to any of claims 15-17 which comprises the additional step (b) of preparing a compound of
formula III by reacting a Weinreb-type amide compound of formula IV:
with a a halogenating agent; preferably an agent selected from alkyl hypochlorite, alkyl hypobromite, sodium br-
omite, sodium hypochlorite, benzyltrimethylammonium trihalide, N-halosuccinimide, N-halophthalimide, or phe-
nyliodine (III) bis(trifluoroacetate) (PIFA).
19. A process according to claim 18 wherein the halogenating agent is alkyl hypochlorite, preferably ter-butyl hypochlo-
rite, or sodium hypochlorite.
20. A process according to anyone of claims 15-19 which comprises the additional step (c) of producing the compound
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of formula IV by reacting a compound of formula V with a compound of formula VI:
wherein W, Y, Z, R1, R2, R3, R4, R5 are as previously defined and
L is a nucleophilic leaving group, preferably halogen.
21. A compound of formula III:
wherein R1, R2, R3, R4, Z, Y, W are as defined in anyone of claims 1-14
R5 is hydrogen or alkyl;
Hal is F, Cl, Br, I or SO2F3.
22. A compound of formula IV:
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wherein R1, R2, R3, R4, Z, Y, W are as defined in anyone of claims 1-14 and R5 is hydrogen or susbtituted or
unsubstituted alkyl.
23. Use of a compound as defined in any of claims 1-14 as a UV absorber.
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